Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.
Orkin C, Paterson A, Elias A, Smuk M, Ring K, Volny-Anne A, Calmy A, Hazra A, Geretti AM, Radix A, Titanji BK, Spire B, Del Rio C, Foster C, Moore CB, Cortes CP, Mussini C, Kuritzkes DR, Tan DHS, Martinez E, Wit FWNM, Cresswell F, Venter WDF, Levy I, Zucker J, Molina JM, Hoy J, Arribas J, Llibre JM, Currier J, Rockstroh J, Sutinen J, Gebo K, Waters L, Gisslen M, O'Reilly M, Boffito M, Thompson M, Parczewski M, John M, Gandhi M, Kumarasamy N, Paton N, Mackie N, Cahn P, Elion R, Noe S, Walmsley S, Collins S, Cole-Haley S, Apea V, Short WR, Gilleece Y, Paparini S.
Orkin C, et al. Among authors: parczewski m.
Lancet HIV. 2025 Sep;12(9):e649-e659. doi: 10.1016/S2352-3018(25)00131-6. Epub 2025 Aug 4.
Lancet HIV. 2025.
PMID: 40774264
Free article.